Antidotes to haemorrhage: recombinant factor VIIa.
Best Pract Res Clin Haematol
; 17(1): 183-97, 2004 Mar.
Article
in En
| MEDLINE
| ID: mdl-15171966
ABSTRACT
Recombinant Factor VIIa (rFVIIa) concentrates were originally developed to treat the refractory bleeding complications associated with allo-antibody inhibitors in hemophilias A and B. As experience was gained in the hemophilias, the physiology of rFVIIa and its successes in controlling bleeds stimulated rFVIIa use in other challenging medical conditions complicated by bleeding. Thus, rFVIIa has assumed the role of a 'universal pancoagulant' without sufficient evidence-based data from well-designed, adequately powered clinical trials. This chapter discusses the anecdotal experience with rFVIIa based upon the few controlled trials that do exist, and emphasizes that these empirical dosing strategies have not yielded the best approach to achieve effective control of bleeding. Evidence-based data are necessary to establish the cost-benefit and risk-benefit profiles of rFVIIa, and to establish it as a standard treatment for bleeding.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Recombinant Proteins
/
Factor VII
/
Hemorrhage
Type of study:
Etiology_studies
Limits:
Humans
Language:
En
Journal:
Best Pract Res Clin Haematol
Journal subject:
HEMATOLOGIA
Year:
2004
Document type:
Article
Affiliation country:
United States